Table 3.
Assay category | Critical prevalence level (%) required to attain: |
|||||||
---|---|---|---|---|---|---|---|---|
PPV of: |
NPV of: |
|||||||
≥85% | ≥90% | ≥95% | ≥99% | ≥85% | ≥90% | ≥95% | ≥99% | |
PCR-DNA sequencing targeted at pncA mutations | ≥29 | ≥39 | ≥58 | ≥88 | ≤67 | ≤56 | ≤38 | ≤10 |
Other molecular assays targeting pncA mutationsb | ≥17 | ≥25 | ≥41 | ≥78 | ≤90 | ≤85 | ≤73 | ≤34 |
Wayne assay | ≥17 | ≥25 | ≥41 | ≥78 | ≤66 | ≤55 | ≤36 | ≤10 |
Based on estimates of sensitivity and specificity obtained in the final meta-analysis. CI, confidence interval; DOR, diagnostic odds ratio; LR, likelihood ratio; NPV, negative predictive values; PPV, positive predictive value.
Comprises line probe assay, microarray, branch migration inhibition, and denaturing gradient gel electrophoresis.